Alkyl and alkoxyethyl antineoplastic phospholipids

Journal of Medicinal Chemistry

Volumn 39, Issue 13, 1996, Pages 2609-2614

  Koufaki, Maria ^a   Polychroniou, Vanessa ^a   Calogeropoulou, Theodora ^a   Tsotinis, Andrew ^b   Drees, Markus ^c   Fiebig, Heiner H ^c   LeClerc, Sophie ^d   Hendriks, Hans R ^e   Makriyannis, Alexandros ^f  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF FREIBURG   (Germany)

^d STATION BIOLOGIQUE   (France)

^e EORTC NDDO   (Netherlands)

^f UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEXADECYL 2 (1 METHYLPIPERIDINO)ETHYL PHOSPHATE; MILTEFOSINE; PHOSPHOLIPID DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE;

ANIMALS; ANTINEOPLASTIC AGENTS; CDC2 PROTEIN KINASE; CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; CYCLINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MITOSIS; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHOLIPIDS; PHOSPHONIC ACIDS; PHOSPHOPROTEIN PHOSPHATASE; PIPERIDINES; STARFISH; TUMOR CELLS, CULTURED;

EID: 0029941194     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9509152     Document Type: Article

References (41)

1. (a) Berdel, W. E.; Bausert, W. R. E.; Fink U.; Rastetter, J.; Munder, P. G. Anti-Tumor Action of Alkyl-Lysophospholipids (Review). Anticancer Res. 1981, 1, 345-352.
2. (b) Berdel, W. E.; Andreesen, R.; Munder, P. G. Synthetic Alkyl-Phospholipid Analogs: A New Class of Antitumor Agents. In Phospholipids and Cancer Regulations; Kuo, J. F., Ed.; CRC Press: Boca Raton, FL, 1985; Vol. 2, pp 41-73.
3. (c) Crumpton, S. C.; Goz, B.; Ishaq K. S. Novel Lipid Analogs with Cytostatic and Cytocidal Activity. Anticancer Res. 1988, 8, 1361-1366.
4. (d) Munder, P. G.; Westphal, O. Antitumoral and Other Biomedical Activities of Synthetic Ether Lysophospholipids. Chem. Immunol. 1990, 49, 206-235.
5. (e) Andreesen, R. Ether Lipids in the Therapy of Cancer. Prog. Biochem. Pharmacol. 1988, 22, 118-131.
6. (f) Baumann, W. J., Ed. Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids. Lipids 1991, 26, 965-1449.
7. (g) Daniel, L. W. Ether Lipids in Experimental Cancer Chemotherapy. In Cancer Chemotherapy; Hickman, J. A., Tritton, T. R., Eds.; Blackwell Scientific Publications: Oxford, 1993; Vol. 6, pp 146-178.
8. (h) Papadimitriou, C. A.; Lali, P. Ether Lipids and their Derivatives. A New Class of Antineoplastic Drugs. Pharmakeftiki 1993, 6, 103-116.
9. Munder, P. G.; Westphal, O. Lysolecithin-Type Antitumore Drugs. German Patent 2,619,686, November 24, 1977; Chem Abstr. 1978, 88, 83718f.
10. (a) Unger, C.; Eibl, H.; Nagel, G. A.; von Heyden, H. W.; Breiser, A.; Engel, J.; Stekar, J.; Peuker, M.; Hilgard, P.; Berger, M. Hexadecylphosphocholine in the Topical Treatment of Skin Metastases: A Phase I trial. In New Drugs in Oncology; Queisser, W., Fiebig, H. H., Eds.; Karger: New York, 1989; pp 219-223.
11. (b) Danhauser-Riedl, S.; Himmelmann, A.; Steinhauser, G.; Busch, R.; Vogler, W. R.; Rastetter, J.; Berdel, W. E. Cytotoxic Effects of Hexadecylphosphocholine in Neoplastic Cell Lines Including Drug-Resistant Sublines in Vitro. J. Lipid Mediators 1990, 2, 271-280.
12. (a) Neumann, H. A.; Herrmann, D. B. J.; Boerner, D. Inhibition of Human Tumor Colony Formation by the New Alkyl Lysophospholipid Ilmofosine. J. Natl. Cancer Soc. 1987, 78, 1087-1093.
13. (b) Lazenby, C. M.; Thompson, M. G.; Hickman, J. A. Elevation of Leukemic Cell Intracellular Calcium by the Ether Lipid SRI 62-834. Cancer Res. 1990, 50, 3327-330.
14. (c) Honma, Y.; Kasukabe, T.; Okabe-Kado, J.; Hozumi, M.; Tsushima, S.; Nomura, H. Antileukemic Effect of Alkyl Phospholipids. Cancer Chemother. Pharmacol. 1983, 11, 73-76.
15. (d) Zheng, B.; Oishi, K.; Shoji, M.; Eibl, H.; Berdel, W. E.; Hajdu, J.; Vogler, W. R.; Kuo, J. F. Inhibition of Protein Kinase C, (Sodium Plus Potassium)-Activated Adenosine Triphosphatase, and Sodium Pump by Synthetic Phospholipid Analogues. Cancer Res. 1990, 50, 3025-3031.
16. (e) Bonjouklian, R.; Phillips, M. L.; Kuhler, K. M.; Grindey, G. B.; Poore, G. A.; Schultz, R. M.; Altom, M. G. Studies of the Antitumor Activity of (2-Alkoxyalkyl)- and (2-Alkoxyalkenyl)phosphocholines. J. Med. Chem. 1986, 29, 2472-2477.
17. (f) Houlihan, W. J.; Lee, M. L.; Munder, P. G.; Winslow, C. M.; Cheon, S. H.; D'Aries, F. J.; DeLillo, A. K.; Jaeggi, C. S.; Mason, R. B.; Parrino, V. A. Cyclic Oxygen Analogues of Alkyl-Lysophospholipids. Synthesis and Neoplastic Cell Growth Inhibitory Properties. J. Lipid Mediators 1990, 2, 295-307.
18. (g) Morris-Natschke, S. L.; Gumus, F.; Marasco, C. J., Jr.; Meyer, K. L.; Marx, M.; Piantadosi, C.; Layne, M. D.; Modest, E. J. Synthesis of Phospho-Choline and Quarternary Amine Ether Lipids and Evaluation of in Vitro Antineoplastic Activity. J. Med. Chem. 1993, 36, 2018-2025.
19. (a) Modolell, M.; Andreesen, R.; Pahlke, W.; Brugger, U.; Munder, P. G. Disturbance of Phospholipid Metabolism during the Selective Destruction of Tumor Cells Induced by Alkyl-Lysophospholipids. Cancer Res. 1979, 39, 4681-4686.
20. (b) Hoffman, D. R.; Hoffman, L. H.; Snyder F. Cytotoxicity and Metabolism of Alkyl Phospholipid Analogues in Neoplastic Cells. Cancer Res. 1986, 46, 5803-5809.
21. (c) Berkovic, D.; Berkovic, K.; Fleer, E. A. M.; Eibl, H.; Unger, C. Inhibition of Calcium-Dependent Protein Kinase C by Hexadecylphosphocholine and 1-O-Octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not Correlate With Inhibition of Proliferation of HL60 and K562 Cell Lines. Eur. J. Cancer 1994, 30A, 509-515.
22. Berdel, W. E. Ether Lipids and Derivatives as Investigational Anticancer Drugs. Onkologie 1990, 13, 245-250.
23. Unger, C.; Damenz, W.; Fleer, E. A. M.; Kim, D. J.; Breiser, A.; Hilgard, P.; Engel, J.; Nagel, G.; Eibl, H. Hexadecylphosphocholine, a New Ether Lipid Analogue. Acta Oncol. 1989, 28, 213-217.
24. Unger, C.; Eibl, H. Hexadecyl Phosphocholine: Preclinical and the First Clinical Results of a New Antitumor Drug. Lipids 1991, 26, 1412-17.
25. (a) Eibl, H. Compositions Containing Hexadecylphosphocholine and Alkylglycerols and Uses Thereof. U. S. Patent 4,837,023, June 6, 1989.
26. (b) Eibl, H.; Unger, C. Hexadecylphosphocholine: a New and Selective Antitumor Drug. Cancer Treat. Rev. 1990, 17, 233-242.
27. (c) Shoji, M.; Raynor, R. L.; Fleer, E. A. M.; Eibl, H.; Vogler, W. R.; Kuo, J. F. Effects of Hexadecylphosphocholine on Protein Kinase C and TPA-Induced Differentiation of HL60 Cells. Lipids 1991, 26, 145-149.
28. (d) Voegeli, R.; Echarti, C.; Maurer, H. R.; Stekar, J.; Hilgard, P.; Unger, C. Selective Cytostatic Activity of Hexadecylphosphocholine Against Tumor Cells in Vitro Leads to the Establishment of an in Vivo Screening System for Phospholipid analogues. Int. J. Oncol. 1993, 2, 161-164.
29. (e) Geilen, C. C.; Wieder, T.; Haase, A.; Reutter, W.; Morré, D. M.; Morré, D. J. Uptake, Subcellular Distribution and Metabolism of the Phospholipid Analogue Hexadecylphosphocholine in MDCK Cells. Biochim. Biophys. Acta 1994, 1211, 14-22.
30. Unger, C.; Eibl, H.; Breiser, A.; Von Heyden, H. W.; Engel, J.; Hilgard, P.; Sindermann, H.; Peukert, M.; Nagel, G. A. Hexadecylphosphocholine (D18506) in the Topical Treatment of Skin Metastases: A Phase-I Trial. Onkologie 1988, 11, 295-296.
31. Berdel, W. E.; Becher, R.; Edler, L.; Bremer, K.; Essers, U.; Drozd, A.; Zafferani, A.; Klee, M. A. G.; Bachmann, P.; Korfel, A.; Westerhausen, M. Daily Oral Miltefosine (hexadecylphosphocholine) in Patients with Advanced Non-Small Cell Lung Cancer. A Phase II Study. Onkologie 1992, 15, 238-242.
32. 3. J. Org. Chem. 1992, 57, 6156-6163.
33. (b) Duclos, R. I. Jr.; Chia, H. H.; Abdelmageed, O. H.; Esber, H.; Fournier, D. J.; Makriyannis, A. Syntheses of Racemic and Nearly Optically Pure Ether Lipids and Evaluation of in Vitro Antineoplastic Activities. J. Med. Chem. 1994, 37, 4147-4154.
34. Fiebig, H. H.; Berger, D. P.; Wengler, W. A.; Walbrecher, E.; Winterhalter, B. R. Combined in Vitro/in Vivo Test Procedure with Human Tumor Xenografts for New Drug Development. Contrib. Oncol. 1992, 42, 321-351.
35. Rialet, V.; Meijer, L. A. New Screening Test for Antimitotic Compounds Using the Universal M Phase-Specific Protein Kinase, p34cdc2/Cyclin Bcdc13, Affinity-Immobilized on p13suc1-Coated Microtitration Plates. Anticancer Res. 1991, 11, 1581-1590.
36. Baratte, B.; Meijer, L.; Galaktionov, K.; Beach, D. Screening for Antimitotic Compounds Using the cdc25 Tyrosine Phosphatase, an Activator of the Mitosis-Inducing p34cdc2/Cyclin Bcdc13 Protein Kinase. Anticancer Res. 1992, 12, 873-880.
37. Calogeropoulou, T.; Koufaki, M.; Tsotinis, A.; Balzarini, J.; De Clerq, E.; Makriyannis, A. Synthesis and Anti-HIV Evaluation of Alkyl and Alkoxyethyl Phosphodiester AZT Derivatives. Antival. Chem. Chemother. 1995, 6, 43-49.
38. Arion, D.; Meijer, L.; Brizuela, L.; Beach, D. Cdc2 is a Component of the M-Phase Specific Histone H1 Kinase: Evidence for Identity with MPF. Cell 1988, 55, 371-378.
39. CKSh2. Eur. J. Biochem. 1992, 203, 353-360.
40. Meijer, L.; Arion, D.; Golsteyn, R.; Pines, J.; Brizuela, L.; Hunt, T.; Beach, D. Cyclin is a Component of the Sea Urchin Egg M-Phase Specific Histone H1 Kinase. EMBO J. 1989, 8, 2275-2282.
41. Hamburger, A. W.; Salmon, S. E. Primary Bioassay of Human Tumor Stem Cells. Science 1977, 197, 416-463.